RESUMO
Context: Heart failure (HF) refers to abnormal changes in the function of the body's heart pump under the action of a variety of pathogenic factors. Due to the complex etiology and course of HF, current research on its etiology and pathogenesis hasn't yet reached a clear conclusion. So, there are many manifestations of heart failure in patients, and there are also many changes in the treatment. Objectives: The study intended to evaluate the efficacy of adenovirus-mediated miR-199a nanoparticles (NPs) for heart failure (HF). Design: The research team performed an animal study. Setting: The study took place at Shanghai Pudong Hospital at Fudan University Pudong Medical Center in Shanghai, China. Animals: The animals were 40 healthy, adult, male, Sprague-Dawley (SD) rats. They were specific pathogen-free (SPF) grade SD rats, all weighing about 280 g and aged 7-8 weeks. Intervention: The research team: (1) induced HF using coronary artery ligation and established different HF models and (2) randomly divided the rats into two groups with 20 rats in each group-an experimental group, which received high-dose, microR-199a (miR-199a) NPs, and a control group, which received low-dose miR-199a NPs. The treatments occurred for seven days after the induction of HF. Outcome Measures: At baseline and postintervention, the research team measured the left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), diastolic and systolic left ventricular anterior wall (LVAW) thickness, left ventricular posterior wall (LVPW) thickness, and expression of heat shock protein 27 (HSP27), HSP70, soluble glycoprotein 130 (SGP130). The team analyzed and studied the effects of the adenovirus-mediated miR-199a NP on that expression, based on the above indicators. Results: The miR-199a prepared with NPs had good specificity through observation. The expression of HSP27, SGP130 was significantly downregulated in the experimental group as compared to the control group (P < .05) and HSP70 was upregulated in the experimental group as compared to the control group (P < .05). The expression decreased, or increased, with an increase in the cardiac-function classification, with substantial differences between the control and experimental groups. Expression levels of HSP27, HSP70, and SGP in the experimental group were negatively correlated with those of controls and negatively correlated with the left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), and left ventricular ejection fraction (LVEF). Conclusions: NP had good specificity. The miR-199a NP downregulated levels of HSP, which had a certain protective effect against HF and had a high clinical-adoption and promotion value.
Assuntos
Insuficiência Cardíaca , MicroRNAs , Animais , Masculino , Ratos , Adenoviridae/genética , Adenoviridae/metabolismo , China , Receptor gp130 de Citocina/uso terapêutico , Glicoproteínas/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Insuficiência Cardíaca/metabolismo , Proteínas de Choque Térmico HSP27/uso terapêutico , MicroRNAs/metabolismo , Ratos Sprague-Dawley , Volume Sistólico , Função Ventricular Esquerda , Nanopartículas , Proteínas de Choque Térmico HSP70/metabolismoRESUMO
Cancer is a disease having global consequences. Though several new strategies and treatments have been developed so far, they often come with malicious side effects and this paved ways for demand of naturally extracted/driven product as potent anti-cancer agent owing to their reduced toxicity and side effects. One such common Indian household plant Neem (Azadirachta Indica) and its extract have variegated immunomodulatory effects as anti-cancer agent. Neem Leaf Glycoprotein (NLGP) modifies immune cells present in the tumor surroundings as well as in the peripheral system, rather than directly attacking the cancer cells. NLGP acts as a natural immunomodulator showing several functions like sustained tumor growth regulation by stimulating central and effector memory cells as a vaccination adjuvant, normalization of angiogenic activities, controls hypoxia, improves immune evasion techniques as well as suppresses the activity of several immunological cells (Tregs, myeloid-derived suppressor cells, and tumor-associated macrophages) which promote tumor growth and metastasis in the tumor microenvironment (TME). NLGP prioritises type1 immune-microenvironment which consists of T-bet+IFN-γ-producing group 1 innate lymphoid cell (ILC) (ILC1 and natural killer cells), CD8+ cytotoxic T cells (TC1), and CD4+ T helper1 (Th1) cells. In this review we aim to summarize detailed activity of NLGP in cancer immunoregulation.
Assuntos
Azadirachta , Neoplasias , Glicoproteínas/uso terapêutico , Humanos , Imunidade Inata , Fatores Imunológicos/uso terapêutico , Extratos Vegetais/uso terapêutico , Folhas de Planta , Proteínas de Plantas/uso terapêutico , Linfócitos T Citotóxicos , Microambiente TumoralRESUMO
The treatment for tropical neglected diseases, such as Chagas disease (CD) and leishmaniasis, is extremely limited to a handful of drugs that suffer from unacceptable toxicity, tough administration routes, like parenteral, and increasing treatment failures due to the parasite resistance. Consequently, there is urgency for the development of new therapeutic options to treat such diseases. Since peptidases from these parasites are responsible for crucial functions in their biology, these molecules have been explored as alternative targets. In this context, a myriad of proteolytic inhibitors has been developed against calcium-dependent cysteine-type peptidases, collectively called calpains, which are implicated in several human pathophysiological diseases. These molecules are highly expanded in the genome of trypanosomatids and they have been reported participating in several parasite biological processes. In the present perspective, we discuss our almost two decades of experience employing the calpain inhibitors as an interesting shortcut to a possible repurpose strategy to treat CD and leishmaniasis.
Assuntos
Doença de Chagas , Leishmaniose , Doença de Chagas/tratamento farmacológico , Glicoproteínas/uso terapêutico , Humanos , Leishmaniose/tratamento farmacológico , Inibidores de Proteases/farmacologia , Inibidores de Proteases/uso terapêuticoRESUMO
OBJECTIVE: This study aimed to discuss the influence of nimodipine+ulinastatin on the neurological function and inflammatory reaction in patients with cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH). METHODS: Overall, 90 patients with CVS after SAH who were admitted to our hospital were enrolled in this study and randomly divided into research and control groups (n = 45 for both groups). On the basis of conventional therapy, patients in the control group were injected with ulinastatin and those in the research group were injected with ulinastatin+nimodipine through an intravenous drip for 7 days with the others the same as those of the control group. RESULTS: Blood flow velocity in all cerebral arteries was lower in the research group than in the control group after treatment (P < 0.05). Calcitonin gene-related peptide and nitric oxide levels were higher in the research group than in the control group after treatment (P < 0.05). Endothelin levels were lower in the research group than in the control group (P < 0.05). The total effective rate was higher in the research group than in the control group (P < 0.05). Glasgow Coma Scale scores were higher in the research group than in the control group (P < 0.05). CONCLUSION: The drug combination of nimodipine and ulinastatin improved blood flow and neurological function in patients with CVS after SAH and enhanced the therapeutic efficacy; the underlying mechanism may be associated with the regulation of vascular endothelial dilatation function and the inhibition of relevant inflammatory factors' expression.
Assuntos
Glicoproteínas/uso terapêutico , Nimodipina/uso terapêutico , Hemorragia Subaracnóidea/complicações , Inibidores da Tripsina/uso terapêutico , Vasodilatadores/uso terapêutico , Vasoespasmo Intracraniano/tratamento farmacológico , Adulto , Velocidade do Fluxo Sanguíneo/efeitos dos fármacos , Artérias Cerebrais/efeitos dos fármacos , Artérias Cerebrais/fisiopatologia , Quimioterapia Combinada , Feminino , Glicoproteínas/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Nimodipina/administração & dosagem , Hemorragia Subaracnóidea/fisiopatologia , Resultado do Tratamento , Inibidores da Tripsina/administração & dosagem , Vasodilatadores/administração & dosagem , Vasoespasmo Intracraniano/etiologia , Vasoespasmo Intracraniano/fisiopatologiaRESUMO
PURPOSE: This study aimed to assess the efficacy of traditional Chinese medicine (TCM) in septic patients treated with ulinastatin. METHODS: PubMed, EmBase, and the Cochrane library were searched up to January 2021 to identify randomized controlled trials. The weight mean difference (WMD) and relative risk (RR) with 95% confidence intervals were used with the random-effects model. RESULTS: Twenty-three randomized controlled trials with 1903 septic patients were included. TCM significantly reduced the APACHE II score (WMD: -5.18; Pâ<â.001), interleukin-6 (WMD: -63.00; Pâ<â.001), tumor necrosis factor-α (WMD: -8.86; Pâ<â.001), c-reactive protein (WMD: -9.47; Pâ<â.001), mechanical ventilation duration (WMD: -3.98; Pâ<â.001), intensive care unit stay (WMD: -4.18; Pâ<â.001), procalcitonin (WMD: -0.53; Pâ<â.001), lipopolysaccharide (WMD: -9.69; Pâ<â.001), B-type natriuretic peptide (WMD: -159.87; Pâ<â.001), creatine kinase isoenzyme MB (WMD: -45.67; Pâ<â.001), cardiac troponin I (WMD: -0.66; Pâ<â.001), and all-cause mortality risk (RR: 0.55; Pâ<â.001). CONCLUSIONS: TCM lowers inflammation levels and reduces the risk of all-cause mortality for septic patients.
Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico , Glicoproteínas/uso terapêutico , Sepse/tratamento farmacológico , Inibidores da Tripsina/uso terapêutico , Medicamentos de Ervas Chinesas/administração & dosagem , Glicoproteínas/administração & dosagem , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento , Inibidores da Tripsina/administração & dosagemRESUMO
The study was aimed at analyzing the protective effects of gintonin in an amyloid beta- (Aß-) induced Alzheimer's disease (AD) mouse model. For the development of the Aß-induced AD mouse model, the amyloid-ß (Aß 1-42) peptide was stereotaxically injected into the brains of mice. Subsequently, gintonin was administered at a dose of 100 mg/kg/day/per oral (p.o) for four weeks daily, and its effects were evaluated by using western blotting, fluorescence analysis of brain sections, biochemical tests, and memory-related behavioral evaluations. To elucidate the effects of gintonin at the mechanistic level, the activation of endogenous antioxidant mechanisms, as well as the activation of astrocytes, microglia, and proinflammatory mediators such as nuclear factor erythroid 2-related factor 2 (NRF-2) and heme oxygenase-1 (HO-1), was evaluated. In addition, microglial cells (BV-2 cells) were used to analyze the effects of gintonin on microglial activation and signaling mechanisms. Collectively, the results suggested that gintonin reduced elevated oxidative stress by improving the expression of NRF-2 and HO-1 and thereby reducing the generation of reactive oxygen species (ROS) and lipid peroxidation (LPO). Moreover, gintonin significantly suppressed activated microglial cells and inflammatory mediators in the brains of Aß-injected mice. Our findings also indicated improved synaptic and memory functions in the brains of Aß-injected mice after treatment with gintonin. These results suggest that gintonin may be effective for relieving AD symptoms by regulating oxidative stress and inflammatory processes in a mouse model of AD. Collectively, the findings of this preclinical study highlight and endorse the potential, multitargeted protective effects of gintonin against AD-associated oxidative damage, neuroinflammation, cognitive impairment, and neurodegeneration.
Assuntos
Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/prevenção & controle , Anti-Inflamatórios/uso terapêutico , Antioxidantes/uso terapêutico , Glicoproteínas/uso terapêutico , Estresse Oxidativo/efeitos dos fármacos , Extratos Vegetais/uso terapêutico , Administração Oral , Animais , Anti-Inflamatórios/farmacologia , Antioxidantes/farmacologia , Modelos Animais de Doenças , Masculino , Camundongos , Extratos Vegetais/farmacologiaRESUMO
Research on milk fat globule membrane (MFGM) is gaining traction. The interest is two-fold; on the one hand, it is a unique trilayer structure with specific secretory function. On the other hand, it is the basis for ingredients with the presence of phospho- and sphingolipids and glycoproteins, which are being used as food ingredients with valuable functionality, in particular, for use as a supplement in infant nutrition. This last application is at the center of this Review, which aims to contribute to understanding MFGM's function in the proper development of immunity, cognition, and intestinal trophism, in addition to other potential effects such as prevention of diseases including cardiovascular disease, impaired bone turnover and inflammation, skin conditions, and infections as well as age-associated cognitive decline and muscle loss. The phospholipid composition of MFGM from bovine milk is quite like human milk and, although there are some differences due to dairy processing, these do not result in a chemical change. The MFGM ingredients, as used to improve the formulation in different clinical studies, have indeed increased the presence of phospholipids, sphingolipids, glycolipids, and glycoproteins with the resulting benefits of different outcomes (especially immune and cognitive outcomes) with no reported adverse effects. Nevertheless, the precise mechanism(s) of action of MFGM remain to be elucidated and further basic investigation is warranted.
Assuntos
Glicolipídeos/uso terapêutico , Glicoproteínas/uso terapêutico , Gotículas Lipídicas/química , Proteínas do Leite/uso terapêutico , Animais , Antígenos de Superfície , Bovinos , Diarreia/tratamento farmacológico , Suplementos Nutricionais , Ingredientes de Alimentos , Glicolipídeos/química , Glicoproteínas/química , Humanos , Imunidade , Lactente , Fórmulas Infantis , Fenômenos Fisiológicos da Nutrição do Lactente , Proteínas do Leite/química , Leite Humano , Fosfolipídeos/química , Fosfolipídeos/uso terapêutico , EsfingolipídeosRESUMO
BACKGROUND: Sepsis is the leading cause of death in critically ill patients. Ulinastatin (UTI), a protease inhibitor, and rhubarb, used as a traditional Chinese medication, are proved to be effective in treating sepsis, but the effect of the combination therapy of these two drugs on sepsis remains unclear. This study aimed to investigate the effect of the combination treatment of UTI and rhubarb on sepsis patients. METHODS: A total of 75 septic patients were randomly divided into control group, UTI group, Rhubarb group, and UTI plus Rhubarb group. Clinical data and score of Acute Physiology and Chronic Health Evaluation II (APACHE II) were collected; lymphocyte subtypes in the peripheral blood were analyzed before and after the 5-day treatment in the Intensive Care Unit. RESULTS: All the therapeutic interventions (UTI alone, rhubarb alone, or UTI plus rhubarb) significantly reduced the levels of C-Reactive protein, white blood cell density, lactic acid, and APACH II scores, and elevated the levels of CD4/CD8, but only UTI plus rhubarb treatment obviously decreased the level of procalcitonin. CONCLUSION: This study suggested that the combination of UTI and rhubarb may be a promising therapeutic scheme to ameliorate sepsis.
Assuntos
Medicamentos de Ervas Chinesas/administração & dosagem , Glicoproteínas/administração & dosagem , Rheum/química , Sepse/tratamento farmacológico , Inibidores da Tripsina/administração & dosagem , Idoso , Idoso de 80 Anos ou mais , Estado Terminal/mortalidade , Quimioterapia Combinada , Medicamentos de Ervas Chinesas/uso terapêutico , Feminino , Glicoproteínas/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Resultado do Tratamento , Inibidores da Tripsina/uso terapêuticoRESUMO
Care of the musculoskeletal system, including the muscles, joints, and bones, is important for a healthy life expectancy in today's aging society. The aim of this randomized, double-blind, placebo-controlled study was to investigate the effect of consumption of milk-fat globule membrane (MFGM) and glucosamine on joint function and physical performance. Participants were healthy Japanese men and women, aged 60-74 y, with a history of mild knee or low back pain at rest. They were randomized to receive tablets containing MFGM 1.0 g+glucosamine 1.5 g or placebo tablets for 8 wk. We assessed passive range of motion, active range of motion (self-reported VAS score), JKOM and JLEQ, and physical performance. Data were available for analysis for 25 participants in the active treatment group and 28 in the placebo group. The active group showed significant improvements in passive range of motion at the knee and active range of motion at both the knee and low back. The active group also showed significant improvements in some physical performance, including obstacle walking speed and speed of ascending stairs. The findings of this study suggest that consumption of a combination of MFGM and glucosamine may improve joint function and physical performance.
Assuntos
Glucosamina/uso terapêutico , Glicolipídeos/uso terapêutico , Glicoproteínas/uso terapêutico , Amplitude de Movimento Articular/efeitos dos fármacos , Caminhada/fisiologia , Idoso , Artralgia/tratamento farmacológico , Suplementos Nutricionais , Método Duplo-Cego , Teste de Esforço/efeitos dos fármacos , Feminino , Glucosamina/farmacologia , Glicolipídeos/farmacologia , Glicoproteínas/farmacologia , Humanos , Articulação do Joelho/fisiologia , Gotículas Lipídicas , Dor Lombar/tratamento farmacológico , Masculino , Pessoa de Meia-IdadeRESUMO
Lectins are proteins or glycoproteins of non-immune origin which have at least one noncatalytic domain that bind reversibly to specific mono or oligosaccharides. Traditional Chinese Medicine (TCM) involves a broad range of medicinal practices sharing common concepts which have been developed in China and are based on a tradition of more than thousands of years. Plant materials which are commonly used in TCM as a complementary or alternative for Western medical treatments contain a considerable number of important lectins. These lectins have been reported to have various applications and uses such as cancer treatment, glycoconjugate research, biomarker development, and others. Here, we summarize the available literature related to lectins from TCM and recent trends in their potential biomedical applications.
Assuntos
Lectinas , Medicina Tradicional Chinesa , Animais , Glicoproteínas/isolamento & purificação , Glicoproteínas/uso terapêutico , Humanos , Lectinas/isolamento & purificação , Lectinas/uso terapêutico , Extratos Vegetais/isolamento & purificação , Extratos Vegetais/uso terapêuticoRESUMO
OBJECTIVE: To observe the clinical therapeutic effects on severe acute pancreatitis (SAP) treated with electroacupuncture (EA), sparse-dense wave and 2 Hz/15 Hz, at Dachangshu (BL 25) and Shangjuxu (ST 37) assisting ulinastetin and explore the effective therapeutic method for SAP. METHODS: A total of 120 patients of SAP were randomized into an observation group and a control group, 60 cases in each one. In the control group, the routine western medicine was adopted with the intravenous drip with ulinastatin. In the observation group, on the basis of the treatment as the control group, EA was applied at Dachangshu (BL 25) and Shangjuxu (ST 37). The treatment was given once every day, 20 min each time. The treatment was 2 weeks in the two groups. The recovery time of defecation, the recovery time of bowel sound, the remission time of abdominal pain and the hospitalization time were recorded in the patients of the two groups. The changes in the tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and amylase, as well as the scores in the acute physiology and chronic health evaluation â ¡ (APACHE â ¡) were compared in the patients of the two groups before treatment, and on the 3rd, 8th and 14th days of treatment. The therapeutic effects, the cases of surgical transfer or the cases of the transfer of intensive care unit (ICU) were compared between the two groups. RESULTS: The recovery time of defecation, the recovery time of bowel sound and the remission time of abdominal pain, as well as the hospitalization time in the observation group were shorter than those in the control group (all P <0.05). The levels of TNF-α, IL-6 and amylase, as well as the scores of APACHE â ¡ on the 3rd, 8th and 14th days of treatment were all reduced as compared with those before treatment in the two groups (all P <0.05). The results in the observation group were lower than those in the control group (all P <0.05). The total effective rate was 95.0% (57/60) in the observation group, better than 81.7% (49/60) in the control group (P <0.05). There were 1 case of surgical transfer and 0 case in ICU transfer in the observation group, 3 cases of surgical transfer and 2 cases in ICU transfer in the control group, indicating the significant differences between the two groups (both P <0.05). . CONCLUSION: EA at Dachangshu (BL 25) and Shangjuxu (ST 37) displays the satisfactory accessory therapeutic effects on SAP treated with ulinastatin.
Assuntos
Eletroacupuntura , Glicoproteínas/uso terapêutico , Pancreatite/terapia , Pontos de Acupuntura , Amilases/sangue , Terapia Combinada , Humanos , Interleucina-6/sangue , Fator de Necrose Tumoral alfa/sangueRESUMO
BACKGROUND: The potential benefits and possible risks associated with Xuebijing when combined with ulinastatin for sepsis treatment are not fully understood. METHODS: Databases, such as PubMed, Web of Science, CNKI, WanFang and VIP, were searched to collect randomized, controlled trials. Studies were screened, data were extracted, and the methodological quality was assessed by two reviewers independently. A meta-analysis was carried out with Stata 11.0 software. RESULTS: A total of 16 studies involving 1192 participants were enrolled for meta-analysis based on the inclusion and exclusion criteria. The results showed that compared with the group using routine therapies and the group using a single administration of either ulinastatin or Xuebijing, the trial group using Xuebijing combined with ulinastatin was significantly superior in the following aspects: mortality (RRâ¯=â¯0. 54,95% CI (0. 41, 0. 70, Pâ¯=â¯.000), 7â¯d APACHE II (SMDâ¯=â¯-1.21, 95%CI (-1.62, -0.80), Pâ¯=â¯.000), duration of mechanical ventilation (SMDâ¯=â¯-1.21, 95%CI (-1.62, -0.80), Pâ¯=â¯.000), average length of time in the intensive care unit (SMDâ¯=â¯-1.21, 95%CI (-1.62, -0.80), Pâ¯=â¯.000), incidence of multiple organ dysfunction syndromes (RRâ¯=â¯0. 54, 95% CI (0.41, 0. 70, Pâ¯=â¯.000), interleukin-6 (SMDâ¯=â¯-1.36,95%CI (-2.46, -0.27), Pâ¯=â¯.000), lipopolysaccharide (SMDâ¯=â¯-9.92, 95%CI (-11.7, -7.90), Pâ¯=â¯.006), and procalcitonin (SMDâ¯=â¯-0.30, 95%CI (-0.34, -0.26), Pâ¯=â¯.012). CONCLUSIONS: Our results found that Xuebijing when combined with ulinastatin was superior to both routine therapies and the single administration of either ulinastatin or Xuebijing. This finding provides a new therapeutic option for the treatment of sepsis.
Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico , Glicoproteínas/uso terapêutico , Sepse/tratamento farmacológico , Inibidores da Tripsina/uso terapêutico , Quimioterapia Combinada , Medicamentos de Ervas Chinesas/administração & dosagem , Glicoproteínas/administração & dosagem , Humanos , Inibidores da Tripsina/administração & dosagemRESUMO
Pulmonary fibrosis is a chronic, progressive, lethal lung disease characterized by alveolar cell necrosis and dysplasia of interstitial fibrotic tissue, resulting in loss of lung function and eventual respiratory failure. Previously, glucocorticoid drugs were used to treat this lung disorder. However, positive responses were recorded in less than half of treated patients and the cytotoxicity caused by high dosage treatment is still a concern. The present study investigated whether ulinastatin, a typical urinary trypsin inhibitor that mitigates numerous inflammatory responses, could be a treatment option for lung fibrosis. The results demonstrated that ulinastatin had the ability to ameliorate interstitial fibrosis and alveolar exudates and to protect against lung diseases induced by smoke, irradiation or silica particles. The mechanism of ulinastatin resulted in the downregulation of inflammatory cascades: Transforming growth factorß1, tumor necrosis factorα and nuclear factorκB, as demonstrated by western blotting and ELISA. Ulinastatin treatment with a high dose (100,000 U/kg body weight/day) resulted in an attenuated inflammatory response, and inhibited fibrosis formation in lungs, suggesting that ulinastatin may become a part of a clinical therapeutic strategy.
Assuntos
Glicoproteínas/farmacologia , Fibrose Pulmonar/tratamento farmacológico , Inibidores da Tripsina/farmacologia , Animais , Regulação para Baixo , Avaliação Pré-Clínica de Medicamentos , Glicoproteínas/uso terapêutico , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Pulmão/patologia , Masculino , NF-kappa B/metabolismo , Fibrose Pulmonar/metabolismo , Ratos Sprague-Dawley , Transdução de Sinais , Fator de Crescimento Transformador beta1/metabolismo , Inibidores da Tripsina/uso terapêutico , Fator de Necrose Tumoral alfa/metabolismoRESUMO
The purpose of the present study was to evaluate the cardioprotective effect of ulinastatin against isoproterenolinduced chronic heart failure (CHF). Compared with the control group, treatment with ulinastatin decreased interventricular septal thickness and left ventricular posterior wall thickness, and improved the left ventricular ejection fraction, left ventricular fractional shortening and peak E and peak A ratio in the isoproterenolinduced CHF rat. In addition, ulinastatin suppressed inflammation, oxidative stress and apoptosis in heart tissue from isoproterenolinduced CHF rats. Ulinastatin induced the activation of the phosphatidylinositol 3kinase (PI3K)/RACα serine/threonine protein kinase (Akt) signaling pathway and downregulated the p38 mitogenactivated protein kinase (MAPK) and nuclear factor (NF)κB pathway in isoproterenolinduced CHF rats. These data demonstrated the cardioprotective effect of ulinastatin against isoproterenolinduced chronic heart failure through the PI3KAkt, p38 MAPK and NFκB pathways.
Assuntos
Cardiotônicos/farmacologia , Glicoproteínas/farmacologia , Insuficiência Cardíaca/tratamento farmacológico , Sistema de Sinalização das MAP Quinases , Animais , Cardiotônicos/uso terapêutico , Avaliação Pré-Clínica de Medicamentos , Glicoproteínas/uso terapêutico , Insuficiência Cardíaca/induzido quimicamente , Isoproterenol , Masculino , Miocárdio/patologia , NF-kappa B/metabolismo , Estresse Oxidativo , Fosfatidilinositol 3-Quinases/metabolismo , Ratos Sprague-Dawley , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismoRESUMO
BACKGROUND: Ulinastatin (UTI) plays the beneficial roles in modifying cerebral ischemic injury evoked by cardiac arrest (CA). XueBiJing (XBJ), comprised of extracts from Chinese herbals, has been used for the treatment of sepsis and ischemic disorders linked to multiple organ dysfunction syndromes. The current study was to find interventions that can enhance effectiveness of these drugs and further to provide a fundamental for their rational application in clinical practice. Thus, we examined how apoptosis signal in the hippocampus is engaged in a facilitating role of UTI and XBJ in improving neural injury and neurological functions after transient cerebral ischemia. METHODS: CA was induced by asphyxia followed by cardiopulmonary resuscitation in rats. Western Blot analysis and ELISA were employed to determine the protein expression of Caspase-3 and Caspase-9 in the hippocampus; and representative apoptosis pathways. The modified neurological severity score (mNSS) and spatial working memory performance were used to assess neurological deficiencies in CA rats. RESULTS: CA increased Caspase-3 and Caspase-9 in the hippocampus CA1 region. A lower dose of UTI did not attenuate upregulation of apoptosis signal pathways evoked by CA. However, a systemic administration of XBJ significantly amplified the inhibitory effects of the lower dose of UTI on apoptosis signal of the hippocampus. In addition, a combination of UTI and XBJ improved mNSS and spatial working memory performance to a greater degree. CONCLUSIONS: Our data indicate that a combination of XBJ and UTI plays a facilitating role in improving neuronal injury and neurological deficits observed in transient cerebral ischemia; and an inhibition of apoptosis signal pathways is involved in neuroprotective effects of united XBJ and UTI.
Assuntos
Apoptose/efeitos dos fármacos , Medicamentos de Ervas Chinesas/uso terapêutico , Glicoproteínas/uso terapêutico , Hipocampo/efeitos dos fármacos , Ataque Isquêmico Transitório/tratamento farmacológico , Fármacos Neuroprotetores/uso terapêutico , Animais , Asfixia , Quimioterapia Combinada , Medicamentos de Ervas Chinesas/administração & dosagem , Glicoproteínas/administração & dosagem , Injeções Intraperitoneais , Ataque Isquêmico Transitório/metabolismo , Masculino , Fármacos Neuroprotetores/administração & dosagem , Ratos , Ratos Wistar , Transdução de Sinais/efeitos dos fármacosRESUMO
The success of cancer vaccines is limited as most of them induce corrupted CD8+ T cell memory populations. We reported earlier that a natural immunomodulator, neem leaf glycoprotein (NLGP), therapeutically restricts tumor growth in a CD8+ T cell-dependent manner. Here, our objective is to study whether memory CD8+ T cell population is generated in sarcoma hosts after therapeutic NLGP treatment and their role in prevention of post-surgery tumor recurrence, in comparison to the immunostimulatory metronomic cyclophosphamide (CTX) treatment. We found that therapeutic NLGP and CTX treatment generates central memory CD8+ T (TCM) cells with characteristic CD44+CD62LhighCCR7highIL-2high phenotypes. But these TCM cells are functionally impaired to prevent re-appearance of tumors along with compromised proliferative, IL-2 secretive and cytotoxic status. This might be due to the presence of tumor load, even a small one in the host, which serves as a persistent source of tumor antigens thereby corrupting the TCM cells so generated. Surgical removal of the persisting tumors from the host restored the functional characteristics of memory CD8+ T cells, preventing tumor recurrence after surgery till end of the experiment. Moreover, we observed that generation of superior TCM cells in NLGP treated surgically removed tumor hosts is related to the activation of Wnt signalling in memory CD8+ T cells with concomitant inhibition of GSK-3ß and stabilisation of ß-catenin, which ultimately activates transcription of Wnt target genes, like, eomesodermin, a signature molecule of CD8+ TCM cells.
Assuntos
Azadirachta/química , Linfócitos T CD8-Positivos/imunologia , Glicoproteínas/imunologia , Memória Imunológica , Recidiva Local de Neoplasia/prevenção & controle , Extratos Vegetais/imunologia , Sarcoma/imunologia , Animais , Antígenos de Neoplasias , Linhagem Celular Tumoral , Ciclofosfamida/administração & dosagem , Ciclofosfamida/imunologia , Ciclofosfamida/uso terapêutico , Citotoxicidade Imunológica , Glicoproteínas/uso terapêutico , Imunoterapia , Camundongos , Recidiva Local de Neoplasia/imunologia , Recidiva Local de Neoplasia/cirurgia , Extratos Vegetais/administração & dosagem , Extratos Vegetais/química , Extratos Vegetais/uso terapêutico , Folhas de Planta/química , Folhas de Planta/imunologia , Sarcoma/prevenção & controle , Sarcoma/cirurgia , Via de Sinalização Wnt , beta Catenina/genéticaRESUMO
We investigated the effects of ulinastatin on early postoperative cognitive dysfunction (POCD) after one-lung ventilation (OLV) surgery in elderly patients receiving neoadjuvant chemotherapy. Eighty elderly patients with preoperative neoadjuvant chemotherapy scheduling for radical esophagectomy under OLV were recruited. They were randomly divided into an ulinastatin pretreatment group (U group, n = 40) and a control group (C group, n = 40). The U group received 10,000 U/kg ulinastatin before anesthesia and 5000 U/kg daily on postoperative days 1 to 3, while C group received saline. Levels of interleukin (IL)-6, IL-10, C-reactive protein (CRP), and S-100ß protein were assayed before surgery, at the end of surgery, and on postoperative days 1 and 3. Patients underwent cognitive assessment 1 day before and 7 days after surgery. 38 patients in U group and 37 patients in C group completed the neuropsychological tests. The U group had a lower incidence of POCD than C group (23.7 % versus 45.9 %, P = 0.043). The levels of S-100ß protein, IL-6, IL-10, and CRP in both groups increased after surgery. The postoperative concentrations of S-100ß protein, IL-6, and CRP in U group were lower than those in C group. On postoperative day 3, compared with C group, the level of CRP in U group was lower, while that of IL-10 was higher. These findings demonstrate that ulinastatin can attenuate the elevation of S100ß protein levels and the incidence of POCD, most likely by the mechanism of reducing serum IL-6 and CRP levels and increasing IL-10 levels.
Assuntos
Transtornos Cognitivos/tratamento farmacológico , Transtornos Cognitivos/etiologia , Glicoproteínas/uso terapêutico , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Terapia Neoadjuvante/efeitos adversos , Ventilação Monopulmonar/efeitos adversos , Complicações Pós-Operatórias/tratamento farmacológico , Complicações Pós-Operatórias/etiologia , Idoso , Idoso de 80 Anos ou mais , Transtornos Cognitivos/psicologia , Citocinas/metabolismo , Esofagectomia/efeitos adversos , Feminino , Humanos , Masculino , Testes Neuropsicológicos , Complicações Pós-Operatórias/psicologia , Subunidade beta da Proteína Ligante de Cálcio S100/metabolismoRESUMO
BACKGROUND: Postoperative intra-abdominal adhesions are a major cause of morbidity and mortality and contribute to a heavy burden on health care resources. At present, numerous introduced adhesion prevention products have demonstrated some benefit but none are consistently effective. The aim of this study was to examine the effectiveness of recombinant human lubricin in preventing intra-abdominal adhesion formation. MATERIALS AND METHODS: A total of 62 male Wistar Albino rats were randomly assigned to the study. Six rats were used to the initial pilot study and 56 rats were randomized into four groups: (1) control cecal abrasion; (2) treatment cecal abrasion with 0.5 mg/mL lubricin solution; (3) control cecal enterotomy and primary closure; and (4) treatment cecal enterotomy and primary closure with 0.5 mg/mL lubricin solution. Rats were sacrificed at 3 d and 21 d postoperatively for the pilot and main studies, respectively. Macroscopic and microscopic adhesion severity was graded by blinded investigators. RESULTS: For the pilot study, all six rats successfully reached the end point indicating safety of the lubricin gel. In the main randomized study, adhesions in the treated cecal abrasion group were significantly reduced both macroscopically (P = 0.001) and microscopically (fibrosis P = 0.009, inflammation P < 0.0001), when compared with the control group. In the cecal enterotomy group, adhesions were reduced for the treatment group in macroscopic (P = 0.011) and microscopic grading (fibrosis P = 0.500, inflammation P = 0.206) compared with the control group. CONCLUSIONS: Recombinant human lubricin significantly reduced both macroscopic and microscopic intra-abdominal adhesions in the cecal abrasion group. The cecal enterotomy group showed modest macroscopic adhesion reduction. Future study using higher concentration of lubricin solution are needed to investigate its toxicity and more profound antiadhesion properties in significant operations.
Assuntos
Glicoproteínas/uso terapêutico , Aderências Teciduais/prevenção & controle , Animais , Avaliação Pré-Clínica de Medicamentos , Humanos , Masculino , Projetos Piloto , Ratos , Ratos Wistar , Proteínas Recombinantes/uso terapêuticoRESUMO
The purpose of the study was to test a novel treatment that carbodiimide-derivatized-hyaluronic acid-lubricin (cd-HA-lubricin) combined cell-based therapy in an immobilized flexor tendon repair in a canine model. Seventy-eight flexor tendons from 39 dogs were transected. One tendon was treated with cd-HA-lubricin plus an interpositional graft of 8 × 10(5) BMSCs and GDF-5. The other tendon was repaired without treatment. After 21 day of immobilization, 19 dogs were sacrificed; the remaining 20 dogs underwent a 21-day rehabilitation protocol before euthanasia. The work of flexion, tendon gliding resistance, and adhesion score in treated tendons were significantly less than the untreated tendons (p < 0.05). The failure strength of the untreated tendons was higher than the treated tendons at 21 and 42 days (p < 0.05). However, there is no significant difference in stiffness between two groups at day 42. Histologic analysis of treated tendons showed a smooth surface and viable transplanted cells 42 days after the repair, whereas untreated tendons showed severe adhesion formation around the repair site. The combination of lubricant and cell treatment resulted in significantly improved digit function, reduced adhesion formation. This novel treatment can address the unmet needs of patients who are unable to commence an early mobilization protocol after flexor tendon repair.
Assuntos
Transplante de Medula Óssea , Glicoproteínas/uso terapêutico , Fator 5 de Diferenciação de Crescimento/uso terapêutico , Traumatismos da Mão/cirurgia , Ácido Hialurônico/análogos & derivados , Traumatismos dos Tendões/cirurgia , Animais , Cães , Avaliação Pré-Clínica de Medicamentos , Traumatismos da Mão/tratamento farmacológico , Ácido Hialurônico/uso terapêutico , Distribuição Aleatória , Traumatismos dos Tendões/tratamento farmacológico , Transplante AutólogoRESUMO
OBJECTIVE: To investigate the effects of ulinastatin(UTI) on postoperative cognitive function in patients undergoing coronary artery bypass grafting. METHODS: One hundred and twenty-seven patients undergoing elective coronary artery bypass surgery were randomly divided into three groups:high-dose UTI group(16000 U/kg i.v.), low-dose UTI group(8000 U/kg i.v.) and control group(normal saline). The levels of plasma cortisol were measured before and one day after surgery. The level of IL-6, IL-10, TNF-α and S100ß were measured before operation(T0), at open chest(T1), end of operation(T2), 6 h(T3)and 24 h(T4) after operation. A neuropsychological test scale was to evaluate the cognitive function 1 day before operation, 1 week and 3 months after operation. RESULTS: Ninety-three patients completed the study. There was no significant difference in general information of patients among three groups(P>0.05). The level of plasma cortisol one day after operation was significantly higher than that before operation in control group(P<0.01). The levels of plasma cortisol in high-dose UTI group and low-dose UTI group were lower than that of control group(P<0.01). In all groups, the level of plasma IL-6, IL-10, TNF-α and S100B increased remarkably at T2, T3, T4 compared to those at T0(all P<0.05). The level of plasma IL-6, TNF-α(at T2, T3, T4)and S100ß(at T3)in high-dose UTI group and low-dose UTI group were all lower than those of control group(P<0.05),while there were no significant differences between high-dose UTI group and low-dose UTI group(P>0.05). The incidence of postoperative cognitive dysfunction in POCD 1 week after operation in high-dose UTI and low-dose UTI groups(25.8% and 23.3%)was lower than that in control group(50.0%), while there were no significant difference 1 month after operation between high-dose UTI group(12.9%) or low-dose UTI group(16.7%)and control group(28.1%). The level of plasma S100ß at T2 of POCD patients(n=31)was higher than that of non-POCD group(n=62)(P<0.05). CONCLUSION: Ulinastatin can reduce the incidence of postoperative cognitive dusfunction 1 week after coronary artery bypass surgery, which might be associated with inhibition of inflammation and S100ß expression.